Eos BioInnovation

Autoimmunity BioSolutions is a biotechnology company developing innovative solutions for autoimmune diseases, with a focus on multiple sclerosis. Their core technology involves a next-generation immuno-corrective therapy, tailored to a specific genetic subgroup of autoimmune patients. This therapy aims to restore normal immune function by targeting a specific genetic variant (SNP) driving the autoimmune pathology. The company's platform enables targeted modulation of the immune system, offering potential clients a means to correct immune system dysfunction with precision therapies.

HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. The company employs a unique two-site binding mechanism in its targeted therapeutics platform, which enhances the safety and efficacy of treatments while addressing significant unmet medical needs. By concentrating on the root causes of these diseases, HDAX Therapeutics strives to improve patient outcomes and provide long-lasting solutions for various pathologies, including neuropathies and cardiometabolic disorders.